CD44 and neoplasm: Researchers have developed a polymeric chitosan-coated nanoparticle encapsulated with doxorubicin capable of binding specifically to CD44 receptors, thereby eliminating CD44+ cancer stem-like cells and reducing tumor size and cytotoxicity without causing systemic toxicity (382).